Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes.

Abstract

OBJECTIVES The purpose of this study was to compare the outcome of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (MI) when performed with or without the platelet glycoprotein IIb/IIIa antibody, abciximab. BACKGROUND Abciximab improves the outcome of angioplasty but the effect of abciximab in primary angioplasty has… (More)

Topics

8 Figures and Tables

Slides referencing similar topics